piracetam has been researched along with Baltic Myoclonic Epilepsy in 7 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disabling myoclonus is the main symptom in long-standing Unverricht-Lundborg disease (ULD), and levetiracetam (LEV) appears to be an effective anticonvulsant with promising short-term antimyoclonic properties." | 2.71 | Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. ( Gelisse, P; Genton, P; Magaudda, A, 2004) |
| "Levetiracetam appears to be a useful antimyoclonic agent in cases of progressive myoclonic epilepsy and should be considered for adjunctive therapy." | 1.34 | Levetiracetam in three cases of progressive myoclonus epilepsy. ( Kkolou, E; Papacostas, S; Papathanasiou, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KH | 1 |
| Song, JS | 1 |
| Park, CW | 1 |
| Ki, CS | 1 |
| Heo, K | 1 |
| Kälviäinen, R | 2 |
| Genton, P | 3 |
| Andermann, E | 1 |
| Andermann, F | 1 |
| Magaudda, A | 2 |
| Frucht, SJ | 1 |
| Schlit, AF | 1 |
| Gerard, D | 1 |
| de la Loge, C | 1 |
| von Rosenstiel, P | 1 |
| Crest, C | 1 |
| Dupont, S | 1 |
| Leguern, E | 1 |
| Adam, C | 1 |
| Baulac, M | 1 |
| Gelisse, P | 2 |
| Papacostas, S | 1 |
| Kkolou, E | 1 |
| Papathanasiou, E | 1 |
| Khyuppenen, J | 1 |
| Koskenkorva, P | 1 |
| Eriksson, K | 1 |
| Vanninen, R | 1 |
| Mervaala, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht[NCT00357669] | Phase 3 | 50 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht[NCT00368251] | Phase 3 | 56 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The range for Action Myoclonus Score (centrally read) is 0 (best) - 160 (worst). Percent change from Baseline = 100 X ((Baseline UMRS4 - Treatment UMRS4) / Baseline UMRS4). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 17.45 |
| Brivaracetam 5 mg/Day | -4.60 |
| Brivaracetam 150 mg/Day | 12.34 |
The range for Functional Disability Score is 0 (best) to 28 (worst). Percent change from Baseline = 100 X ((Baseline UMRS5 - Treatment UMRS5) / Baseline UMRS5). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 0.00 |
The range for Myoclonus Patient Questionnaire is 0 (best) to 44 (worst). Percent change from Baseline = 100 X ((Baseline UMRS1 - Treatment UMRS1) / Baseline UMRS1). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | -9.68 |
| Brivaracetam 5 mg/Day | 0.00 |
| Brivaracetam 150 mg/Day | 5.41 |
The range for Stimulus Sensitivity Score is 0 (best) to 17 (worst). Percent change from Baseline = 100 X ((Baseline UMRS3 - Treatment UMRS3) / Baseline UMRS3). Baseline is defined as the last non-missing value prior to or on Randomization Visit. (NCT00368251)
Timeframe: Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | Percent change (Median) |
|---|---|
| Placebo | 0.00 |
| Brivaracetam 5 mg/Day | 43.44 |
| Brivaracetam 150 mg/Day | 0.00 |
The Global Evaluation Scale Score (Investigator) ranges from 1 (Marked worsening) to 7 (Marked improvement). (NCT00368251)
Timeframe: End of Treatment Period (Week 14 or Early Discontinuation Visit)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Brivaracetam 150 mg/Day | 11.1 | 11.1 | 33.3 | 33.3 | 5.6 | 5.6 | 0 |
| Brivaracetam 5 mg/Day | 10.0 | 0 | 30.0 | 50.0 | 10.0 | 0 | 0 |
| Placebo | 0 | 11.1 | 33.3 | 50.0 | 0 | 0 | 5.6 |
1 review available for piracetam and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
Clinical picture of EPM1-Unverricht-Lundborg disease.
Topics: Adolescent; Adult; Age of Onset; Animals; Anticonvulsants; Clonazepam; Cystatin B; Cystatins; Diagno | 2008 |
2 trials available for piracetam and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Metho | 2016 |
Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Drug Therapy, Combination; Female; Humans; Levetir | 2004 |
4 other studies available for piracetam and Baltic Myoclonic Epilepsy
| Article | Year |
|---|---|
First Molecular Diagnosis of a Patient with Unverricht-Lundborg Disease in Korea.
Topics: Adult; Anticonvulsants; Blotting, Southern; Cystatin B; Female; Genetic Predisposition to Disease; H | 2018 |
Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients.
Topics: Activities of Daily Living; Adolescent; Anticonvulsants; Child; Drug Evaluation; Drug Therapy, Combi | 2004 |
Levetiracetam in three cases of progressive myoclonus epilepsy.
Topics: Activities of Daily Living; Adult; Anticonvulsants; Drug Therapy, Combination; Female; Humans; Levet | 2007 |
Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Encephalitis; Epilepsies, Myoclonic; Humans; Hypo | 2001 |